Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study

Authors
Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: b983b3fe6b7ac32e5ace04e9f7baecb8d0bafc00
First added on: Feb 15, 2025